Accelerating Product Innovation and Availability

Improving how prevention is delivered

Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.

Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.

AVAC’s work supports:

The Latest on Accelerating Product Innovation

Event

The Future of HIV Prevention: A People’s Research Agenda for Speed, Scale and Equity

Featured speaker Jeanne Marrazzo, former Director of the National Institute of Allergy and Infectious Diseases and AVAC board member, will cover with us what the People’s Research Agenda tracks, why it matters, and the advocacy priorities that will shape the future of prevention R&D.

Event

The Quest For An HIV Cure — Will It Be Discovered in Africa?

We will explore what has been happening in terms of HIV cure research in Africa, and discuss opportunities to support more Africa-focused HIV cure research.

Infographic

Broadly Neutralizing Antibody Combinations

Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.